FIBRIN-DERIVED PEPTIDE B.BETA.15-42

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 18:19:48 GMT 2023` Edited by `admin` on `Sat Dec 16 18:19:48 GMT 2023`
Protein Type	PEPTIDE
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	A4M8648R4L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FIBRIN-DERIVED PEPTIDE B.BETA.15-42

Common Name

English

BBETA(15-42)

Common Name

English

L-ARGININE, GLYCYL-L-HISTIDYL-L-ARGINYL-L-PROLYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-PROLYL-L-SERYL-L-LEUCYL-L-ARGINYL-L-PROLYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-L-ISOLEUCYL-L-SERYLGLYC

Systematic Name

English

FX-O6

Code

English

FX 06 [WHO-DD]

Common Name

English

FX-06

Code

English

FX06

Code

English

GLYCYL-L-HISTIDYL-L-ARGINYL-L-PROLYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-PROLYL-L-SERYL-L-LEUCYL-L-ARGINYL-L-PROLYL-L-ALANYL-L-PROLYL-L-PROLYL-L-PROLYL-L-ISOLEUCYL-L-SERYLGLYCYLGLYCYLGLYC

Systematic Name

English

Code System Code Type Description

CAS

88650-17-3

Created by admin on Sat Dec 16 18:19:48 GMT 2023 , Edited by admin on Sat Dec 16 18:19:48 GMT 2023

PRIMARY

FDA UNII

A4M8648R4L

Created by admin on Sat Dec 16 18:19:48 GMT 2023 , Edited by admin on Sat Dec 16 18:19:48 GMT 2023

PRIMARY

PUBCHEM

16208062

Created by admin on Sat Dec 16 18:19:48 GMT 2023 , Edited by admin on Sat Dec 16 18:19:48 GMT 2023

PRIMARY

Related Record Type Details


					A4M8648R4L

FIBRIN-DERIVED PEPTIDE B.BETA.15-42

ACTIVE MOIETY

Comments:

Class: Anti-inflammatory, Peptide; Mechanism of Action: Cadherin 5 modulator, Fibrin inhibitor; Highest Development Phases: Phase I for Capillary leak syndrome, Delayed graft function, Shock, Systemic inflammatory response syndrome, Discontinued for Reperfusion injury; Most Recent Events: 28 Jan 2014 Discontinued - Phase-II for Reperfusion injury in Europe (IV), 01 Jan 2014 Phase-I clinical trials in Shock in Austria (IV), 01 Jan 2014 Phase-I clinical trials in Systemic inflammatory response syndrome in Austria (IV)

Amount:


					A4M8648R4L

FIBRIN-DERIVED PEPTIDE B.BETA.15-42

ACTIVE MOIETY

Comments:

RESULTS: Allografts from Bbeta(15-42) treated animals showed less myocardial necrosis (2.5% +/- 2.5% vs. 18.4% +/- 9.2%, P=0.0019) and decreased values of cardiac troponin-T (1.1 +/- 0.6 ng/mL vs. 2.7+/-2.3 ng/mL, P=0.0045), reduced number of infiltrating leukocytes (7.2 +/- 13.6 vs. 49.2 +/- 34.9 per high power field, P=0.0045), and superior cardiac output (78.1 +/- 1.8 mL/min vs. 21.7 +/- 4 mL/min, P = 0.0034). Hearts exposed to 0 and 4 hr of ischemia showed no severe signs of myocardial damage. CONCLUSION: Bbeta(15-42) ameliorates the ischemia-reperfusion injury in transplanted hearts during extended cold ischemia by reduction of infiltrating leukocytes. This experimental protocol provides evidence that Bbeta(15-42) may play a useful role in organ preservation, but clinical evaluation is warranted.

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL